Systematic Identification of Genomic Markers for Guiding Iron Oxide Nanoparticles in Cervical Cancer Based on Translational Bioinformatics

References

• Dissanayake S, Denny WA, Gamage S, Sarojini V. Recent developments in anticancer drug delivery using cell penetrating and tumor targeting peptides. J Control Release. 2017;250:62–76. doi:10.1016/j.jconrel.2017.02.006
   PubMed Web of Science ®Google Scholar
• Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29(25):3457–3465. doi:10.1200/JCO.2011.34.7625
   PubMed Web of Science ®Google Scholar
• Jahangirian H, Kalantari K, Izadiyan Z, Rafiee-Moghaddam R, Shameli K, Webster TJ. A review of small molecules and drug delivery applications using gold and iron nanoparticles. Int J Nanomedicine. 2019;14:1633–1657. doi:10.2147/IJN.S184723
   PubMed Web of Science ®Google Scholar
• Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17(1):20–37. doi:10.1038/nrc.2016.108
   PubMed Web of Science ®Google Scholar
• Peng XH, Qian X, Mao H, et al. Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy. Int J Nanomedicine. 2008;3(3):311–321. doi:10.2147/ijn.s2824
   PubMed Web of Science ®Google Scholar
• Talluri S, Malla RR. Superparamagnetic Iron Oxide Nanoparticles (SPIONs) for diagnosis and treatment of breast, ovarian and cervical cancers. Curr Drug Metab. 2019;20:942–945. doi:10.2174/1389200220666191016124958
   PubMed Web of Science ®Google Scholar
• Wahajuddin AS. Superparamagnetic iron oxide nanoparticles: magnetic nanoplatforms as drug carriers. Int J Nanomedicine. 2012;7:3445–3471. doi:10.2147/IJN.S30320
   PubMed Web of Science ®Google Scholar
• Douziech-Eyrolles L, Marchais H, Herve K, et al. Nanovectors for anticancer agents based on superparamagnetic iron oxide nanoparticles. Int J Nanomedicine. 2007;2(4):541–550.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Sun Y, Shen J, et al. Iron/iron oxide core/shell nanoparticles for magnetic targeting MRI and near-infrared photothermal therapy. Biomaterials. 2014;35(26):7470–7478. doi:10.1016/j.biomaterials.2014.04.063
   PubMed Web of Science ®Google Scholar
• Jeon M, Halbert MV, Stephen ZR, Zhang M. Iron oxide nanoparticles as T1 contrast agents for magnetic resonance imaging: fundamentals, challenges, applications, and prospectives. Adv Mater. 2021;33(23):1906539. doi:10.1002/adma.201906539
   Web of Science ®Google Scholar
• Lee C-W, Wu P-C, Hsu I-L, et al. New templated Ostwald ripening process of mesostructured FeOOH for third-harmonic generation bioimaging. Small. 2019;15(20):1805086. doi:10.1002/smll.201805086
   Web of Science ®Google Scholar
• Liao MY, Wu CH, Lai PS, et al. Surface state mediated NIR Two‐Photon fluorescence of iron oxides for nonlinear optical microscopy. Adv Funct Mater. 2013;23(16):2044–2051. doi:10.1002/adfm.201202676
   Web of Science ®Google Scholar
• Di Marco M, Sadun C, Port M, Guilbert I, Couvreur P, Dubernet C. Physicochemical characterization of ultrasmall superparamagnetic iron oxide particles (USPIO) for biomedical application as MRI contrast agents. Int J Nanomedicine. 2007;2(4):609–622.
   PubMed Web of Science ®Google Scholar
• Jain TK, Reddy MK, Morales MA, Leslie-Pelecky DL, Labhasetwar V. Biodistribution, clearance, and biocompatibility of iron oxide magnetic nanoparticles in rats. Mol Pharm. 2008;5(2):316–327. doi:10.1021/mp7001285
   PubMed Web of Science ®Google Scholar
• Ansari MO, Ahmad MF, Shadab GG, Siddique HR. Superparamagnetic iron oxide nanoparticles based cancer theranostics: a double edge sword to fight against cancer. J Drug Deliv Sci Technol. 2018;45:177–183. doi:10.1016/j.jddst.2018.03.017
   Web of Science ®Google Scholar
• Chang T-W, Ko H, Huang W-S, et al. Tannic acid-induced interfacial ligand-to-metal charge transfer and the phase transformation of Fe3O4 nanoparticles for the photothermal bacteria destruction. Chem Eng J. 2022;428:131237. doi:10.1016/j.cej.2021.131237
   Web of Science ®Google Scholar
• Pyataev NA, Petrov PS, Minaeva OV, et al. Amylase-sensitive polymeric nanoparticles based on dextran sulfate and doxorubicin with anticoagulant activity. Polymers. 2019;11(5):921. doi:10.3390/polym11050921
   PubMed Web of Science ®Google Scholar
• Ashrafizadeh M, Ahmadi Z, Kotla NG, et al. Nanoparticles targeting STATs in cancer therapy. Cells. 2019;8(10):1158. doi:10.3390/cells8101158
   PubMed Web of Science ®Google Scholar
• Sun C, Du K, Fang C, et al. PEG-mediated synthesis of highly dispersive multifunctional superparamagnetic nanoparticles: their physicochemical properties and function in vivo. ACS Nano. 2010;4(4):2402–2410. doi:10.1021/nn100190v
   PubMed Web of Science ®Google Scholar
• Kheirkhah P, Denyer S, Bhimani AD, et al. Magnetic drug targeting: a novel treatment for intramedullary spinal cord tumors. Sci Rep. 2018;8(1):11417. doi:10.1038/s41598-018-29736-5
   PubMed Web of Science ®Google Scholar
• Srisa-Nga K, Mankhetkorn S, Okonogi S, Khonkarn R. Delivery of superparamagnetic polymeric micelles loaded with quercetin to hepatocellular carcinoma cells. J Pharm Sci. 2019;108(2):996–1006. doi:10.1016/j.xphs.2018.08.008
   PubMed Web of Science ®Google Scholar
• Nagesh PKB, Johnson NR, Boya VKN, et al. PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer. Colloids Surf B Biointerfaces. 2016;144:8–20. doi:10.1016/j.colsurfb.2016.03.071
   PubMed Web of Science ®Google Scholar
• Alarifi S, Ali D, Alkahtani S, Alhader MS. Iron oxide nanoparticles induce oxidative stress, DNA damage, and caspase activation in the human breast cancer cell line. Biol Trace Elem Res. 2014;159(1–3):416–424. doi:10.1007/s12011-014-9972-0
   PubMed Web of Science ®Google Scholar
• Zanganeh S, Hutter G, Spitler R, et al. Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. Nat Nanotechnol. 2016;11(11):986–994. doi:10.1038/nnano.2016.168
   PubMed Web of Science ®Google Scholar
• Casalini T, Limongelli V, Schmutz M, et al. Molecular modeling for nanomaterial-biology interactions: opportunities, challenges, and perspectives. Front Bioeng Biotechnol. 2019;7:268. doi:10.3389/fbioe.2019.00268
   PubMed Web of Science ®Google Scholar
• Wist AD, Berger SI, Iyengar R. Systems pharmacology and genome medicine: a future perspective. Genome Med. 2009;1(1):11. doi:10.1186/gm11
   PubMed Web of Science ®Google Scholar
• Frueh FW, Huang SM, Lesko LJ. Regulatory acceptance of toxicogenomics data. Environ Health Perspect. 2004;112(12):A663–664. doi:10.1289/ehp.112-1277121
   PubMed Web of Science ®Google Scholar
• Kann MG. Advances in translational bioinformatics: computational approaches for the hunting of disease genes. Brief Bioinform. 2010;11(1):96–110. doi:10.1093/bib/bbp048
   PubMed Web of Science ®Google Scholar
• Overby CL, Tarczy-Hornoch P. Personalized medicine: challenges and opportunities for translational bioinformatics. Per Med. 2013;10(5):453–462. doi:10.2217/pme.13.30
   PubMed Web of Science ®Google Scholar
• Tenenbaum JD. Translational bioinformatics: past, present, and future. Genomics Proteomics Bioinformatics. 2016;14(1):31–41. doi:10.1016/j.gpb.2016.01.003
   PubMed Web of Science ®Google Scholar
• Massart R. Preparation of aqueous magnetic liquids in alkaline and acidic media. IEEE Trans Magn. 2003;17(2):1247–1248. doi:10.1109/TMAG.1981.1061188
   Web of Science ®Google Scholar
• Sun X, Dong B, Xu H, et al. Amphiphilic silane modified multifunctional nanoparticles for magnetically targeted photodynamic therapy. ACS Appl Mater Interfaces. 2017;9(13):11451–11460. doi:10.1021/acsami.7b00647
   PubMed Web of Science ®Google Scholar
• Song X-B, Liu G, Liu F, et al. Autophagy blockade and lysosomal membrane permeabilization contribute to lead-induced nephrotoxicity in primary rat proximal tubular cells. Cell Death Dis. 2017;8(6):e2863–e2863. doi:10.1038/cddis.2017.262
   PubMed Web of Science ®Google Scholar
• Repnik U, Hafner Cesen M, Turk B. Strategies for assaying lysosomal membrane permeabilization. Cold Spring Harb Protoc. 2016;2016(6):pdb.top077479. doi:10.1101/pdb.top077479
   Google Scholar
• Shen Y, Gong S, Li J, et al. Co-loading antioxidant N-acetylcysteine attenuates cytotoxicity of iron oxide nanoparticles in hypoxia/reoxygenation cardiomyocytes. Int J Nanomedicine. 2019;14:6103. doi:10.2147/IJN.S209820
   PubMed Web of Science ®Google Scholar
• Wu Q, Jin R, Feng T, et al. Iron oxide nanoparticles and induced autophagy in human monocytes. Int J Nanomed. 2017;12:3993–4005. doi:10.2147/IJN.S135189
   PubMed Web of Science ®Google Scholar
• Assaraf YG, Brozovic A, Goncalves AC, et al. The multi-factorial nature of clinical multidrug resistance in cancer. Drug Resist Updates. 2019;46:100645. doi:10.1016/j.drup.2019.100645
   PubMed Web of Science ®Google Scholar
• Groth-Pedersen L, Jaattela M. Combating apoptosis and multidrug resistant cancers by targeting lysosomes. Cancer Lett. 2013;332(2):265–274. doi:10.1016/j.canlet.2010.05.021
   PubMed Web of Science ®Google Scholar
• Arami H, Khandhar A, Liggitt D, Krishnan KM. In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles. Chem Soc Rev. 2015;44(23):8576–8607. doi:10.1039/c5cs00541h
   PubMed Web of Science ®Google Scholar
• Frtús A, Smolková B, Uzhytchak M, et al. Analyzing the mechanisms of iron oxide nanoparticles interactions with cells: a road from failure to success in clinical applications. J Controlled Release. 2020;328:59–77. doi:10.1016/j.jconrel.2020.08.036
   PubMed Web of Science ®Google Scholar
• Malvindi MA, De Matteis V, Galeone A, et al. Toxicity assessment of silica coated iron oxide nanoparticles and biocompatibility improvement by surface engineering. PLoS One. 2014;9(1):e85835. doi:10.1371/journal.pone.0085835
   PubMed Web of Science ®Google Scholar
• Singh N, Jenkins GJS, Asadi R, Doak SH. Potential toxicity of superparamagnetic iron oxide nanoparticles (SPION). Nano Rev. 2010;1(1):5358. doi:10.3402/nano.v1i0.5358
   PubMedGoogle Scholar
• Huang H, Zhou M, Ruan L, et al. AMPK mediates the neurotoxicity of iron oxide nanoparticles retained in mitochondria or lysosomes. Metallomics. 2019;11(7):1200–1206. doi:10.1039/c9mt00103d
   PubMed Web of Science ®Google Scholar
• Ren X, Chen Y, Peng H, et al. Blocking autophagic flux enhances iron oxide nanoparticle photothermal therapeutic efficiency in cancer treatment. ACS Appl Mater Interfaces. 2018;10(33):27701–27711. doi:10.1021/acsami.8b10167
   PubMed Web of Science ®Google Scholar
• Zhu L, Zhou Z, Mao H, Yang L. Magnetic nanoparticles for precision oncology: theranostic magnetic iron oxide nanoparticles for image-guided and targeted cancer therapy. Nanomedicine. 2017;12(1):73–87.
   PubMed Web of Science ®Google Scholar
• Khan JA, Mandal TK, Das TK, Singh Y, Pillai B, Maiti S. Magnetite (Fe3O4) nanocrystals affect the expression of genes involved in the TGF-beta signalling pathway. Mol Biosyst. 2011;7(5):1481–1486. doi:10.1039/c0mb00192a
   PubMedGoogle Scholar
• Sarin N, Engel F, Rothweiler F, et al. Key players of cisplatin resistance: towards a systems pharmacology approach. Int J Mol Sci. 2018;19(3):767. doi:10.3390/ijms19030767
   PubMed Web of Science ®Google Scholar
• Mattauch S, Sachs M, Behrens J. Liprin-alpha4 is a new hypoxia-inducible target gene required for maintenance of cell-cell contacts. Exp Cell Res. 2010;316(17):2883–2892. doi:10.1016/j.yexcr.2010.06.022
   PubMed Web of Science ®Google Scholar
• Yamasaki A, Nakayama K, Imaizumi A, et al. Liprin-α4 as a possible new therapeutic target for pancreatic cancer. Anticancer Res. 2017;37(12):6649–6654. doi:10.21873/anticanres.12122
   PubMed Web of Science ®Google Scholar
• Onishi H, Yamasaki A, Nakamura K, et al. Liprin-α4 as a new therapeutic target for SCLC as an upstream mediator of HIF1α. Anticancer Res. 2019;39(3):1179–1184. doi:10.21873/anticanres.13227
   PubMed Web of Science ®Google Scholar
• Chen YF, Chiu WT, Chen YT, et al. Calcium store sensor stromal-interaction molecule 1-dependent signaling plays an important role in cervical cancer growth, migration, and angiogenesis. Proc Natl Acad Sci USA. 2011;108(37):15225–15230. doi:10.1073/pnas.1103315108
   PubMed Web of Science ®Google Scholar
• Naser R, Aldehaiman A, Diaz-Galicia E, Arold ST. Endogenous control mechanisms of FAK and PYK2 and their relevance to cancer development. Cancers. 2018;10(6):196. doi:10.3390/cancers10060196
   PubMed Web of Science ®Google Scholar
• Al-Juboori SI, Vadakekolathu J, Idri S, et al. PYK2 promotes HER2-positive breast cancer invasion. J Exp Clin Cancer Res. 2019;38(1):210. doi:10.1186/s13046-019-1221-0
   PubMed Web of Science ®Google Scholar
• Lim ST, Miller NL, Nam JO, Chen XL, Lim Y, Schlaepfer DD. Pyk2 inhibition of p53 as an adaptive and intrinsic mechanism facilitating cell proliferation and survival. J Biol Chem. 2010;285(3):1743–1753. doi:10.1074/jbc.M109.064212
   PubMed Web of Science ®Google Scholar
• Stanzione R, Picascia A, Chieffi P, et al. Variations of proline-rich kinase Pyk2 expression correlate with prostate cancer progression. Lab Invest. 2001;81(1):51–59. doi:10.1038/labinvest.3780211
   PubMed Web of Science ®Google Scholar
• Mendoza-Rodriguez MG, Ayala-Sumuano JT, Garcia-Morales L, Zamudio-Meza H, Perez-Yepez EA, Meza I. IL-1beta inflammatory cytokine-induced TP63 isoform NP63alpha signaling cascade contributes to cisplatin resistance in human breast cancer cells. Int J Mol Sci. 2019;20(2):270. doi:10.3390/ijms20020270
   PubMed Web of Science ®Google Scholar
• De Simone V, Bevivino G, Sedda S, et al. Smad7 knockdown activates protein kinase RNA-associated eIF2α pathway leading to colon cancer cell death. Cell Death Dis. 2017;8(3):e2681–e2681. doi:10.1038/cddis.2017.103
   PubMed Web of Science ®Google Scholar
• Kaczorowski M, Biecek P, Donizy P, Pieniazek M, Matkowski R, Halon A. SMAD7 is a novel independent predictor of survival in patients with cutaneous melanoma. Transl Res. 2019;204:72–81. doi:10.1016/j.trsl.2018.09.002
   PubMed Web of Science ®Google Scholar
• Tyagi N, Song YH, De R. Recent progress on biocompatible nanocarrier-based genistein delivery systems in cancer therapy. J Drug Target. 2019;27(4):394–407. doi:10.1080/1061186X.2018.1514040
   PubMed Web of Science ®Google Scholar
• Si HY, Li DP, Wang TM, et al. Improving the anti-tumor effect of genistein with a biocompatible superparamagnetic drug delivery system. J Nanosci Nanotechnol. 2010;10(4):2325–2331. doi:10.1166/jnn.2010.1913
   PubMed Web of Science ®Google Scholar
• Patel P, Meghani N, Kansara K, Kumar A. Nanotherapeutics for the treatment of cancer and arthritis. Curr Drug Metab. 2019;20(6):430–445. doi:10.2174/1389200220666181127102720
   PubMed Web of Science ®Google Scholar
• Pund S, Pawar S, Gangurde S, Divate D. Transcutaneous delivery of leflunomide nanoemulgel: mechanistic investigation into physicomechanical characteristics, in vitro anti-psoriatic and anti-melanoma activity. Int J Pharm. 2015;487(1):148–156. doi:10.1016/j.ijpharm.2015.04.015
   PubMed Web of Science ®Google Scholar
• Muz B, Buggio M, Azab F, et al. PYK2/FAK inhibitors reverse hypoxia-induced drug resistance in multiple myeloma. Haematologica. 2019;104(7):e310–e313. doi:10.3324/haematol.2018.194688
   PubMed Web of Science ®Google Scholar
• Pasquier J, Gosset M, Geyl C, et al. CCL2/CCL5 secreted by the stroma induce IL-6/PYK2 dependent chemoresistance in ovarian cancer. Mol Cancer. 2018;17(1):47. doi:10.1186/s12943-018-0787-z
   PubMed Web of Science ®Google Scholar
• Xia H, Ooi LL, Hui KM. MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Hepatology. 2013;58(2):629–641. doi:10.1002/hep.26369
   PubMed Web of Science ®Google Scholar
• Guo Y, Fang Q, Ma D, et al. Up-regulation of HO-1 promotes resistance of B-cell acute lymphocytic leukemia cells to HDAC4/5 inhibitor LMK-235 via the Smad7 pathway. Life Sci. 2018;207:386–394. doi:10.1016/j.lfs.2018.06.004
   PubMed Web of Science ®Google Scholar
• Jeon WK, Hong HY, Seo WC, et al. Smad7 sensitizes A549 lung cancer cells to cisplatin-induced apoptosis through heme oxygenase-1 inhibition. Biochem Biophys Res Commun. 2012;420(2):288–292. doi:10.1016/j.bbrc.2012.02.151
   PubMed Web of Science ®Google Scholar
• Yuan Y. Spatial heterogeneity in the tumor microenvironment. Cold Spring Harb Perspect Med. 2016;6(8):a026583. doi:10.1101/cshperspect.a026583
   PubMed Web of Science ®Google Scholar
• McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell. 2017;168(4):613–628. doi:10.1016/j.cell.2017.01.018
   PubMed Web of Science ®Google Scholar
• Swetha KL, Roy A. Tumor heterogeneity and nanoparticle-mediated tumor targeting: the importance of delivery system personalization. Drug Deliv Transl Res. 2018;8(5):1508–1526. doi:10.1007/s13346-018-0578-5
   PubMed Web of Science ®Google Scholar